CR1L抗体;CR1L Antibody—艾普蒂 新品

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P13218(CR1L Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P13218(CR1L Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

The CR1L (Complement Receptor 1-Like) antibody is a tool used to study the CR1L protein, a member of the complement receptor family involved in immune regulation. CR1L shares structural homology with Complement Receptor 1 (CR1), featuring multiple complement control protein (CCP) domains that mediate interactions with complement components like C3b and C4b. It functions as a regulator of the complement cascade, inhibiting excessive activation to prevent host tissue damage. CR1L is expressed in various tissues, including the liver, kidney, and immune cells, and is implicated in both innate immunity and immune complex clearance.

Research on CR1L has gained attention due to its potential role in diseases linked to complement dysregulation, such as autoimmune disorders (e.g., lupus), infectious diseases, and age-related conditions like macular degeneration. CR1L antibodies are critical for detecting protein expression, localization, and interactions in experimental models, including Western blotting, immunohistochemistry, and flow cytometry. They also aid in exploring CR1L’s therapeutic potential, such as targeting complement pathways in inflammatory diseases.

Despite its functional overlap with CR1. CR1L’s distinct expression patterns and regulatory mechanisms remain under investigation. Current studies focus on clarifying its physiological roles and validating its relevance as a biomarker or therapeutic target in complement-mediated pathologies.